Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

• CRISPR-based functional genomics for dissecting therapeutic dependency in primary acute myeloid leukemia samples.

  PMID 41759529 · PMC13036604 · Molecular cell · 2026 · 8 claims · 8 setups

  Full-text index only

  An optimized dual-lentiviral CRISPR-Cas9 knockout system with fluorescent markers, SFFV promoter, and improved sgRNA backbone (LRG2.1) achieves efficient, low-toxicity gene editing in AML PDX and primary patient samples

  aml pdx#2263 molm-13 pdx#062614 crispr pooled domain-focused

• Dasatinib resensitizes BRAF/MEK inhibitor efficacy in patient-derived xenografts from patients with progression on BRAF/MEK inhibitor treatment.

  PMID 41704766 · PMC12907876 · iScience · 2026 · 8 claims · 6 setups

  Full-text index only

  Genomic mutation and copy-number status show weak correlation with total/phospho-protein expression and pathway activation in melanoma PDX and TCGA samples

  pdx discovery cutaneous nsg reverse-phase targeted rppa

• Critical evaluation of drug response prediction models with DrEval.

  PMID 42120410 · PMC13168506 · Nature communications · 2026 · 8 claims · 6 setups

  Full-text index only

  DrEval is a living open-source benchmarking pipeline for unbiased, biologically meaningful evaluation of cancer drug response prediction models, integrating standardized preprocessing, hyperparameter tuning, statistically rigorous evaluation, cross-study benchmarks, and ablation studies.

  ctrpv2 ccle beataml2 pdx_bruna viability drug pdx

• Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities.

  PMID 41037662 · PMC12877751 · Cancer discovery · 2026 · 8 claims · 7 setups

  Full-text index only

  ATAC-seq profiling of osteosarcoma patient samples, PDXs, and PDX-CLs reveals two distinct chromatin accessibility subtypes: early osteoblast-derived (EOD) and late osteoblast-derived (LOD)

  n=8 pdx-derived pdx osteosarcoma atac-seq bulk h3k27ac

• SMARCA4/2 loss reduces BCL-xL expression and confers a druggable MCL1 dependency in cancer.

  PMID 41807550 · PMC13249849 · NPJ precision oncology · 2026 · 8 claims · 8 setups

  Full-text index only

  MCL1 inhibition is synthetic lethal with SMARCA4/2 loss in SCCOHT and NSCLC cells

  nsclc lung smarca4 bin-67 genome-wide drug colony

• The GENEVA platform models tumor mosaicism to reveal variations of responses to KRAS inhibitors and identify improved drug combinations.

  PMID 41735640 · PMC13035475 · Nature cancer · 2026 · 8 claims · 8 setups

  Full-text index only

  GENEVA is a scalable single-cell-resolution platform for measuring drug responses across genetically diverse pooled 2D/3D cultures and xenograft models

  pooled pool nsg mosaic scrna-seq crispri mitotracker

• Single-cell protein activity analysis reveals aberrant myogenesis and IGF2-PI3K pathway dependencies in MYOD1-mutant rhabdomyosarcoma.

  PMID 41758938 · PMC12947870 · Science advances · 2026 · 8 claims · 8 setups

  Has reproduction · 84

  MYOD1 L122R-mutant SRMS tumors contain three coexisting, conserved cell states (progenitor, transition, differentiated) reflecting aberrant myogenic differentiation

  patient-derived tumor single paired single-nucleus infercnv aracne-ap